Department of Biology, Brigham Young University, Provo, UT 84602, USA.
Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA,
Clin Interv Aging. 2018 Dec 28;14:73-79. doi: 10.2147/CIA.S159148. eCollection 2019.
Alzheimer's disease (AD) is mainly a late-onset neurodegenerative disorder. Substantial efforts have been made to solve the complex genetic architecture of AD as a means to identify therapeutic targets. Unfortunately, to date, no disease-altering therapeutics have been developed. As therapeutics are likely to be most effective in the early stages of disease (ie, before the onset of symptoms), a recent focus of AD research has been the identification of protective factors that prevent disease. One example is the discovery of a rare variant in the 3'-UTR of that is protective for AD. Here, we review the possible genetic, molecular, and functional role of RAB10 in AD and potential therapeutic approaches to target RAB10.
阿尔茨海默病(AD)主要是一种迟发性神经退行性疾病。为了解决 AD 复杂的遗传结构,以确定治疗靶点,人们进行了大量的努力。不幸的是,迄今为止,尚未开发出改变疾病的治疗方法。由于治疗方法可能在疾病的早期阶段(即症状出现之前)最为有效,因此 AD 研究的最近重点是确定预防疾病的保护因素。一个例子是在 的 3'-UTR 中发现了一种罕见的变异,该变异对 AD 具有保护作用。在这里,我们回顾了 RAB10 在 AD 中的可能遗传、分子和功能作用,以及针对 RAB10 的潜在治疗方法。